Dr. Ravi Pyaraka is doctorate in management studies with over 25 years of experience working in various MNC of IT, Healthcare, BioTechnology. A Visionary who combines business acumen with operational expertise & technology to accelerate andtransform the culture stressing accountability, execution, and empowerment to deliver exceptional results.

PharmaDEM a brain child organization founded by Dr.Ravi Pyaraka is aimed to set up its precedence as a consulting and services organization providing digital twin solutions at early stage and late stage of Drug Discovery & Drug Development life cycle in Global Pharmaceutical & Bio Technology Industries.

Dr. Ravi Pyaraka in PharmaDEM iteratively works on establishing a strategic plan that accounts for the needs of the Pharma customer,Work with organization influencers to build a mutual profitable propositions by instilling the technology transformations, Digital Innovation methods which controls and optimizes the processes.

Dr. Ravi Pyaraka, heading towards a successful leadership by supervising and stirring all scale of techno operations & functions in order to maintain continual Customer Success.

Dr.Ravi has more than 17 years of cross functional experience in synthetic chemistry, Computational chemistry, Solid state chemistry, Process chemistry, Pre-formulation, Absorption modelling, Predictive toxicology, Drug device development and Lab automation. He has specific expertise in Drug design, Model driven formulation optimization, Skin permeation modelling and Genotoxicity assessment.

He has done Ph.D. in Medicinal chemistry, Post doc in predictive thermodynamics and was trained under pioneer scientists in the areas of PBPK modelling, Predictive toxicology, Formulation optimization, Membrane permeation modelling and Predictive thermodynamics.

Ravi worked with GVKBIO, Dr Reddy’s Labs Ltd. and Eli Lilly and Company. He established big size integrated modelling & Lab automation COE’s during his experience. Apart from collaboration with top universities in the world, Ravi also served as co-chair for International computational chemistry consortium.

Ravi has proven expertise in small molecules, peptides and biomolecules drug product development with contributions to 20+ ANDAs 5+ 505B2 and 5+ NDAs. He has multiple publications, patents and made a significant contribution to 6 NCE drugs that are currently marketed.

Dr. Deepa G is a Ph.D. graduate in Machine Learning and an innovative research scientist who is having 10+ years of experience in digital innovation &transformation.

Dr.Deepa has deep expertise in databases, Lab notebooks, ML, AI, NLP and automation with sound knowledge in healthcare/pharma domain and practices innovation in pharma product development and solving critical process, formulation challenges by intercepting science, technology and health systems.

Dr. Deepa plays an important role in deriving our platforms and products, which are designed to integrate computational methods with experimental data to enhance the R&D productivity and probability of success.

Dr. Deepa G is a go-getter & an ambitious leader and believes that combination of AI, computing power, data and automation is becoming progressively important for pharmaceutical product development. She has about 8 international publications and two book chapters in the area of machine learning, image analysis and AI-automation and are listed on ResearchGate.

Dr. Rambabu was a postdoctoral research fellow in the department of pharmacology and pharmaceutical Sciences, school of pharmacy, at the University of Southern California, USA from 2006 - 2008.

He obtained a Ph.D. degree from the department of chemistry, Osmania University. With over 60 publications in National and International Journals and 3 patents in the area of medicinal chemistry and computer-aided drug design studies, his scientific expertise spans across therapeutic areas such as Inflammation, Oncology, and Metabolic disorders and vast expertise in design and synthesis of focused antiviral agents, protein prediction and binding site analysis, structure-based drug design and analogues-based drug design.

Dr. Rambabu research efforts have resulted in the identification of novel bioactive compounds for HER-2, HIV-Integrase, GSK3β, CDK-2, PKCδ, TG2, HedgeHog, VLA-4, PTP1B and PLK1 with potential use in treatment of a Cancer.